BIO's 19.1% monthly rally is backed by digital PCR gains and steadier diagnostics, but weak Life Science demand and a rich valuation loom.

ABT's Medical Devices growth is fueled by electrophysiology, expanding CGM adoption and a cardiovascular pipeline extending into 2029 and beyond.

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how research tools & consumables stocks fared in Q2, starting with Thermo Fisher (NYSE:TMO).

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.

Thermo Fisher Scientific has underperformed the broader market over the past year, yet analysts remain highly bullish about the stock’s prospects.

PTC Therapeutics (NASDAQ:PTCT) plans to acquire the ST-920 Fabry disease gene therapy asset through a competitive bankruptcy auction, positioning the company to add a potential one-time treatment to its rare disease portfolio while using its existing global commercial and regulatory infrastructure.

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

European private equity firm Astorg will run the business as an independent diagnostics company, led by former PerkinElmer CEO Dirk Bontridder.

LivaNova PLC recently reported second-quarter 2026 results showing sales rising to US$390.59 million and net income climbing to US$108.57 million, alongside higher earnings per share versus a year earlier. On the back of this performance, the company raised its 2026 constant-currency revenue growth guidance to a range of 8% to 9% and secured a long-term oxygenator supply agreement with Thermo Fisher Scientific to support manufacturing expansion. Now we’ll examine how the raised 2026 growth...

LivaNova (LIVN) raised its full year 2026 revenue and earnings guidance after reporting record quarterly revenue and significantly higher profitability, supported by demand for its Essenz heart-lung machine and a new supply agreement with Thermo Fisher Scientific. See our latest analysis for LivaNova. LivaNova's recent guidance lift comes after a strong run in the share price, with a 90 day share price return of 12.71% and a year to date share price return of 33.21%. The 1 year total...

Arcturus Therapeutics (NASDAQ:ARCT) is positioning its mRNA platform around two rare-disease programs targeting cystic fibrosis and ornithine transcarbamylase deficiency, while its vaccine business is intended to help support therapeutic development, President and CEO Joseph Payne said during a Cana

Thermo Fisher Scientific (NYSE:TMO) mostly sells the instruments and supplies that let other companies do science, not the treatments themselves. So when the company said on July 29 that it had launched the PPD CorEvitas Vitiligo Registry on July 14, to track how patients with nonsegmental vitiligo respond to treatment, it pointed to a quieter […]

Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 1% and th